High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis

BACKGROUND: Tumor mutation burden (TMB) is an important biomarker to predict response to anti-PD-L1 treatment across cancer types. TruSight Oncology 500 (TSO500) is currently used globally as a routine assay for TMB. METHODS: Between 2019 and 2021, 1744 patients with cancer received TSO500 assay as...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Jaeyun, Heo, You Jeong, Park, Sehhoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152061/
https://www.ncbi.nlm.nih.gov/pubmed/37094985
http://dx.doi.org/10.1136/jitc-2022-006454

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152061/
https://www.ncbi.nlm.nih.gov/pubmed/37094985
http://dx.doi.org/10.1136/jitc-2022-006454

Ejemplares similares